Skip to main content

Gritstone bio, Inc.

GRTSDelisted Mar 5, 2025
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001656634

Gritstone bio, Inc. was delisted on Mar 5, 2025; its insiders filed their last Form 4 on Apr 8, 2025; 56 institutions reported holding it in 13F filings for Q3 2024, worth $20.7M in total; no superinvestor held it.

Key figures

Market cap
–
Not available
Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
56
Q3 2024, −22 vs. previous quarter
13F value
$20.7M
Reported value at the end of Q3 2024
Superinvestors holding
0
At the end of Q3 2024

From SEC filings, in USD.

Revenue, FY2023
$16.3M
−18.1% year over year
Net income, FY2023
-$138.5M
No comparable prior period
Free cash flow, FY2023
-$126.2M
No comparable prior period
Revenue, Q2 FY2024
$921.0K
−52.9% year over year

Revenue flow, FY2023

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2023: $138.5M (847.3% of revenue).

Superinvestors holding GRTS, Q3 2024

Go to the superinvestors tab

No superinvestor reported holding GRTS at the end of Q3 2024.

Latest insider trades

See all insider trades

Open-market purchases and sales by Gritstone bio, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Dec 20, 2024 (view filing)4:15 PM ETDec 182 daysEconomides VassilikiEVP, CHIEF FINANCIAL OFFICERSSale−12.0K$0.015−$180−4.6%250.4K after
May 17, 2024 (view filing)May 161 dayAllen Andrew RPRESIDENT AND CEOSSale−24.3K$0.75−$18.2K−2.4%985.4K after
May 17, 2024 (view filing)May 161 dayJones ErinEVP, CHIEF OPERATING OFFICERSSale−13.7K$0.75−$10.3K−3.7%359.3K after
May 17, 2024 (view filing)May 161 dayJooss KarinSEE REMARKSSSale−13.7K$0.75−$10.3K−2.0%683.5K after
May 17, 2024 (view filing)May 161 dayHawryluk MatthewEVP, CHIEF BUSINESS OFFICERSSale−9.26K$0.75−$6.94K−2.9%313.9K after
May 17, 2024 (view filing)May 161 dayEconomides VassilikiEVP, CHIEF FINANCIAL OFFICERSSale−13.7K$0.75−$10.3K−5.0%262.4K after
May 24, 2023 (view filing)May 231 dayEconomides VassilikiSee RemarksPPurchase+12.0K$1.90+$22.8K+5.9%214.1K after
Dec 3, 2021 (view filing)4:47 PM ETDec 12 daysJones ErinChief Operating OfficerSSale−1.00K$13.01−$13.0K−2.1%45.9K after
Dec 3, 2021 (view filing)4:45 PM ETNov 132 daysJones ErinChief Operating OfficerSSale−1.00K$11.14−$11.1K−2.1%45.9K afterAmended
Dec 3, 2021 (view filing)4:43 PM ETOct 1-463 daysJones ErinSee RemarksSSale−2.00K$10.70−$21.4K−4.2%45.9K afterAmended2 lots

Top 10 13F holders, Q3 2024

See all 56 holders

The largest institutional positions in Gritstone bio, Inc. at the end of Q3 2024; share changes are against Q2 2024.

Institutions holding GRTS in Q3 2024
InstitutionSharesValue% of portfolioChange in sharesAction
Morgan Stanley10,295,665$5.97M0.00%+5,841,638+131.2%Added
Redmile Group, LLC4,920,178$2.85M0.17%−187,554−3.7%Reduced
Vanguard Group Inc4,643,928$2.69M0.00%00.0%Unchanged
Versant Venture Management, LLC3,561,150$2.07M3.25%00.0%Unchanged
Siren, L.L.C.3,318,093$1.92M0.10%+3,318,093New
Geode Capital Management, LLC1,246,527$723.0K0.00%+200,857+19.2%Added
Deutsche Bank AG1,245,470$722.4K0.00%−1,983,502−61.4%Reduced
Millennium Management LLC1,140,508$661.4K0.00%+32,332+2.9%Added
BlackRock, Inc.870,271$504.7K0.00%+870,271New
Freestone Capital Holdings, LLC789,719$458.0K0.02%+557,061+239.4%Added

Holders of 5% or more of GRTS

See all 1 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Gritstone bio, Inc..

Largest holders of GRTS from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Redmile Group, LLC13G/A8.20%13.2M shares–Feb 16, 20216 filingsFeb 14, 2025SEC